Skip to search boxSkip to navigationSkip to main content

Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors

  • Laura A. Petrillo(corresponding author)
    ,
  • Denise M. Wolf
    ,
  • Ann M. Kapoun
    ,
  • Nicholas J. Wang
    ,
  • Andrea Barczak
    ,
  • Yuanyuan Xiao
*Corresponding author for this work
  • University of California at San Francisco
    ,
  • OncoMed Pharmaceuticals, Inc.
    ,
  • Oregon Health and Science University
    ,
  • University of Michigan, Ann Arbor
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Though xenografts are used extensively for drug development in breast cancer, how well xenografts reflect the breadth of primary breast tumor subtypes has not been well characterized.Moreover, fewstudies have compared the gene expression of xenograft tumors to the primary tumors from which they were derived. Here we investigate whether the ability of human breast tumors (n = 20) to create xenografts in immune-deficient mice is associated with breast cancer immunohistochemical (IHC) and intrinsic subtype. We also characterize how precisely the gene expression of xenografts reprises that of parent breast tumors, using hierarchical clustering and other correlation-based techniques applied to Agilent 44K gene expression data from 16 samples including four matched primary tumor-xenograft pairs. Of the breast tumors studied, 25 % (5/20) generated xenografts. Receptor and intrinsic subtype were significant predictors of xenograft success, with all (4/4) triple-negative (TN) tumors and no (0/ 12) HR+Her2-tumors forming xenografts (P = 0.0005). Tumor cell expression of ALDH1, a stem cell marker, trended toward successful engraftment (P = 0.14), though CDK5/6, a basal marker, did not. Though hierarchical clustering across the 500 most variable genes segregated human breast tumors from xenograft tumors, when clustering was performed over the PAM50 gene set the primary tumorxenograft pairs clustered together, with all IHC subtypes clustered in distinct groups. Greater similarity between primary tumor-xenograft pairs relative to random pairings was confirmed by calculation of the within-pair between-pair scatter ratio (WPBPSR) distribution (P = 0.0269), though there was a shift in the xenografts toward more aggressive features including higher proliferation scores relative to the primary. Triple-negative breast tumors demonstrate superior ability to create xenografts compared to HR? tumors, which may reflect higher proliferation or relatively stroma-independent growth of this subtype. Xenograft tumors' gene expression faithfully resembles that of their parent tumors, yet also demonstrates a shift toward more aggressive molecular features.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 913-922 (10 pages)

Journal (Volume, Issue Number)

Breast Cancer Research and Treatment (Volume 135, Issue 3)

Publication milestones

  • Published - 10/2012

Publication status

Published - 10/2012

ISSN

0167-6806

Publication IDs

  • Scopus: 84866536411
  • PubMed: 22941572
  • ORCID: /0000-0002-0719-5862/work/58927700

Publication metrics

Metrics

SciVal
FWCI
1.06
SciVal
Author count
15
SciVal
citations
29
SciVal
Paper percentile
85
Fractional count
1
Fractional count
0.07
Fractional count
14
Fractional count
0.93
Fractional count
1
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Citation count
37
Captures
45

Funding Details

Acknowledgments The authors would like to thank the patients who participated in the study. We would like to thank Angie Park for her xenograft development work at OncoMed. This work was supported by funding from OncoMed Pharmaceuticals, Inc. the National Cancer Institute Specialized Program of Research Excellence in Breast Cancer, the Doris Duke Charitable Foundation and the NIH/ NCRR/OD UCSF-CTSI Grant Number TL1 RR024129. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.
FundersFunding numbers
NCRR/OD UCSF-CTSI
TL1 RR024129
OncoMed Pharmaceuticals Inc.
-
NIH
-
NCI
U01CA111234
DDCF
-